TNBC has been shown accounts for 15–20% of breast cancer cases in which there is a lack of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2)8–10. This evidence concerns the gene ERBB2 and breast carcinoma.